Pharmaron Beijing Co (HKSE:03759) Notes Receivable: HK$0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
89 GF Score
Price HK$30.40
GF Value HK$20.50
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Notes Receivable?

Pharmaron Beijing Co HKSE:03759 +4.83% 89 Notes Receivable is HK$0 Mil as of Mar. 2026. GuruFocus rates HKSE:03759 with a GF Score™ of 89/100 and a GF Value™ of HK$20.50 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Pharmaron Beijing Co's Notes Receivable for the quarter that ended in Mar. 2026 was HK$0 Mil.

Pharmaron Beijing Co Notes Receivable Related Terms

Pharmaron Beijing Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Notes Receivable Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:03759
89GF Score
Pharmaron Beijing Co Ltd HKSE:03759
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0 Mil mean?
Pharmaron Beijing Co (HKSE:03759) has a Notes Receivable of HK$0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Notes Receivable too high?
Pharmaron Beijing Co's current Notes Receivable is HK$0 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Notes Receivable compare to VRTX and REGN?
Pharmaron Beijing Co's Notes Receivable of HK$0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Notes Receivable is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$20.50, compared to a current price of HK$30.40 — trading 48.3% above its estimated fair value. The current Notes Receivable is HK$0 Mil. Pharmaron Beijing Co's overall GF Score™ is 89/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Notes Receivable is HK$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of HK$30.40 is trading 48.3% above its estimated GF Value™ of HK$20.50. GuruFocus considers Pharmaron Beijing Co to be Significantly Overvalued.

Key valuation signals for HKSE:03759:

  • Notes Receivable: HK$0 Mil
  • GF Value™: HK$20.50 vs. price of HK$30.40 (48.3% above fair value)
  • GF Score™: 89/100 with 9 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
89GF Score

Get the complete analysis for HKSE:03759

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$30.40
Price
HK$20.50
GF Value